about
Future pharmacological treatments for substance use disordersComputational design of ligand-binding proteins with high affinity and selectivityNicotine Replacement Therapy: An OverviewNew Pharmacological Agents to Aid Smoking Cessation and Tobacco Harm Reduction: What Has Been Investigated, and What Is in the Pipeline?Suppression of Cocaine-Evoked Hyperactivity by Self-Adjuvanting and Multivalent Peptide Nanofiber VaccinesCurrent approaches for the discovery of drugs that deter substance and drug abuse.Psychoactive Substances and the English Language: “Drugs,” Discourses, and Public PolicyNew directions in nicotine vaccine design and use.Facial recognition of heroin vaccine opiates: type 1 cross-reactivities of antibodies induced by hydrolytically stable haptenic surrogates of heroin, 6-acetylmorphine, and morphineLiposomes containing monophosphoryl lipid A: a potent adjuvant system for inducing antibodies to heroin hapten analogs.Hapten optimization for cocaine vaccine with improved cocaine recognitionCan you vaccinate against substance abuse?Substance use in older HIV-infected patients.Cloning and characterization of a hybridoma secreting a 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)-specific monoclonal antibody and recombinant F(ab)The frequency of naive and early-activated hapten-specific B cell subsets dictates the efficacy of a therapeutic vaccine against prescription opioid abuseScientific overview: 2013 BBC plenary symposium on tobacco addiction.Flagellin as carrier and adjuvant in cocaine vaccine development.Immunogenicity of individual vaccine components in a bivalent nicotine vaccine differ according to vaccine formulation and administration conditionsEffect of currently approved carriers and adjuvants on the pre-clinical efficacy of a conjugate vaccine against oxycodone in mice and rats.Effects of an oxycodone conjugate vaccine on oxycodone self-administration and oxycodone-induced brain gene expression in rats.Adjuvants for vaccines to drugs of abuse and addiction.Efficacy, but not antibody titer or affinity, of a heroin hapten conjugate vaccine correlates with increasing hapten densities on tetanus toxoid, but not on CRM197 carriersFuture Challenges for Vaccinologists.Anti-cocaine antibody and butyrylcholinesterase-derived cocaine hydrolase exert cooperative effects on cocaine pharmacokinetics and cocaine-induced locomotor activity in mice.Optimization of a methamphetamine conjugate vaccine for antibody production in miceSubstance use disorders: psychoneuroimmunological mechanisms and new targets for therapy.Prospects, promise and problems on the road to effective vaccines and related therapies for substance abuseA morphine conjugate vaccine attenuates the behavioral effects of morphine in rats.Adenovirus capsid-based anti-cocaine vaccine prevents cocaine from binding to the nonhuman primate CNS dopamine transporter.Rivastigmine reduces "Likely to use methamphetamine" in methamphetamine-dependent volunteers.Nicotine vaccines to treat tobacco dependence.The asthma-chronic obstructive pulmonary disease overlap syndrome: pharmacotherapeutic considerations.Hapten-specific naïve B cells are biomarkers of vaccine efficacy against drugs of abuse.Biologics to treat substance use disorders: Current status and new directionsAssembly and Assessment of DNA Scaffolded Vaccines.A nanoparticle-based nicotine vaccine and the influence of particle size on its immunogenicity and efficacy.Engineering of a hybrid nanoparticle-based nicotine nanovaccine as a next-generation immunotherapeutic strategy against nicotine addiction: A focus on hapten density.Efficacy of D-penicillamine, a sequestering acetaldehyde agent, in the prevention of alcohol relapse-like drinking in rats.An enzymatic advance in nicotine cessation therapy.Investigations into the efficacy of multi-component cocaine vaccines.
P2860
Q22242633-84E1F7B1-B805-42D7-AE64-E07C3A7A0C70Q27679871-588CFD3B-EEA4-4342-9E78-DD15C99B9DFDQ28076733-6099A446-E687-4BF1-ABAB-A191AEFDB7BCQ28277165-7279FC5F-A475-4344-9CC4-7F0ABE8681BFQ28833846-5C888863-B920-4D2F-8018-443B12DD2B5FQ28973615-B14E6658-3722-43EA-8C6D-0AF236E33262Q29398415-604C6A07-2F74-4219-93E7-32AB89E57B30Q33719424-4E71872A-7C91-406E-B58A-5DF8B8C1DCF7Q33874955-56ADC3EC-BE79-476B-BDEE-0E1748242547Q33994987-7E862F80-8A05-498B-9AC3-792E5F0C2E3EQ34021922-444B40EB-CA3A-40F6-88ED-41A7BC1CAA41Q34132788-588213B9-5FE5-4E4D-8474-A7C44FEF0D0BQ34247817-24D09FF4-09F3-4B3B-8362-A3AE4A76AC64Q34334569-62EAE47E-8016-420E-931F-704FB69397FAQ34476304-7A59611B-020A-4BC1-8F5D-3F707DD30F1CQ34487271-433F6E03-6C43-46D8-9E99-DB22E6AAD4F6Q35057556-77C069F6-A237-4440-A935-C12E8D86DBE3Q35061547-6D72EF6F-FFE4-489C-93EA-B30A833EEA33Q35163178-DD63B643-BD42-4515-ABEE-E0B5E4E535B2Q35207004-C1B4E226-18E3-448B-B5B6-400C9C367049Q35493923-9B173584-5193-4E93-BCB9-8144CBF124B6Q35756201-4632983C-A904-4E80-8EBD-38DEF655F076Q35989204-CB80533F-B100-4993-A708-3959D3737107Q36609464-BC537E80-6EE3-4E57-8A50-897E990E8EBDQ36854009-FC3C5EA6-FD25-4942-90A0-03221DFD1EACQ37052393-8B1485CE-B170-41A1-880F-E53764C9CEC5Q37082158-CE9E0463-4C85-4A98-8D6F-73B5E6E08181Q37172159-142D7783-A938-4381-8833-DBD60A0F1188Q37172714-49E14287-60B1-4057-A619-14B581165217Q37425104-E800EC0F-AB85-49AA-A477-21C6AD8666FDQ38056382-8DC75F1A-BB63-42B7-AF19-7B34803E22B3Q38087697-39DFBC24-9ACA-4C70-99A8-34D4469B4C7CQ39519649-A4FA80E0-10F1-4C2E-9FF3-907BB2C06D74Q39576940-37FFFD74-76D1-421E-BD82-D455F39ECB26Q40715556-034AE29D-F6EF-4877-A438-328914921E57Q45040238-AB711B2D-C033-4F6B-9BA2-4C050053F3E8Q45052268-3833AE9E-BB5C-4E59-954D-F0E8E5A3CC1BQ46846272-08B2DEBA-5898-448F-AF1D-9146C8889221Q47199097-BD1F0FDB-3F13-4DD7-AA21-55B4CABDEA9DQ47216341-4D3C360C-7225-4148-B2DF-8AB7A3D63F64
P2860
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Vaccines against drug abuse.
@ast
Vaccines against drug abuse.
@en
type
label
Vaccines against drug abuse.
@ast
Vaccines against drug abuse.
@en
prefLabel
Vaccines against drug abuse.
@ast
Vaccines against drug abuse.
@en
P2093
P2860
P356
P1476
Vaccines against drug abuse.
@en
P2093
P2860
P2888
P356
10.1038/CLPT.2011.281
P407
P577
2011-11-30T00:00:00Z
P5875
P6179
1027143021